Drug Hunter

The "necessary nitrogen" atom has become a fixture in the medicinal chemist's toolbox, and phenyl-to-pyridine ring swaps remain one of the most popular bioisosteric replacements. In this insights article, we focus on an emerging bioisostere, the pyridazin

The First Time Disclosures session at the EFMC International Symposium on Medicinal Chemistry 2026 in Basel, Switzerland, featured eight small molecules presented across two sessions. Organized by the Division of Medicinal Chemistry & Chemical Biology of

Covalent drug discovery continues to expand across target families, modalities, and therapeutic areas. Drug Hunter's covalent warhead reactivity cheat sheet summarizes the relative reactivity of major covalent warhead classes and highlights real-world med

Golidocitinib (AZD4205/DZD4205) is an oral, selective JAK1 inhibitor discovered by AstraZeneca and developed by Dizal for oncology. The molecule applies JAK1-selective pathway inhibition to r/r PTCL, aiming to suppress JAK-STAT-driven lymphoma biology whi

In July 2026, enlicitide (Lipfendra) became the first oral PCSK9 inhibitor approved by the FDA-a feat once thought impossible due to the flat PCSK9-LDLR interaction surface. In Ph. 3 trials, enlicitide demonstrated antibody-like efficacy in adults with hy